[Update in primary glomerular diseases--mainly in IgA nephropathy].
Kawamura
Tetsuga
T
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000502:physiology; D018450:Disease Progression; D005395:Fish Oils / Q000627:therapeutic use; D005920:Glomerular Mesangium / Q000166:cytology; D005922:Glomerulonephritis, IGA / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007678:Kidney Glomerulus / Q000166:cytology; D008264:Macrophages / Q000502:physiology; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D011110:Polymorphism, Genetic; D011379:Prognosis; D013256:Steroids; D013601:T-Lymphocytes / Q000276:immunology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D005395:Fish Oils; D007070:Immunoglobulin A; D007166:Immunosuppressive Agents; D013256:Steroids; D007703:Peptidyl-Dipeptidase A